Line clearance often appears to be a basic GMP activity. However, one leftover label can show that the entire control process failed.
In an anonymized packaging scenario, the previous batch used Product A labels. Some labels fell into a scrap tray. During changeover, the operator removed the main materials, cleaned the area, and completed the checklist. QA then performed a short walk-through before Product B started.
Later, an investigator found Product A label remnants behind a guarding panel and a partially used roll inside a cabinet. Although the next batch carried the correct labels, the physical area did not match the signed clearance record.
Therefore, the issue created a serious mix-up and documentation risk. FDA expectations require manufacturers to remove previous products and unsuitable packaging materials before the next operation and document the result accurately.
Our team addressed the problem by strengthening physical inspection, label control, second-person verification, reconciliation, evidence collection, and CAPA follow-up.
We work with pharmaceutical teams to design, implement, and run effective Quality Management Systems, covering change control, CAPA, deviations, and audits to support consistent GMP compliance.
It should cover actual failure points such as printer cabinets, labeler scrap trays, reject chutes, guarding panels, under-conveyor areas, and line-side storage locations.
A manufacturing site should control their issuance, reconcile issued and used quantities, securely manage returns, and destroy excess lot-coded labels according to approved procedures.
Reconciliation may balance even when physical label remnants remain inside equipment or storage areas. Therefore, teams must combine reconciliation with a complete physical inspection.
